NASDAQ$GBIO
Generation Bio Co · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Generation Bio reported first quarter 2024 financial results and provided updates on its ctLNP and iqDNA platforms.
Generation Bio reported a net loss of $74.5 million for Q1 2024. The company's cash, cash equivalents, and marketable securities totaled $233.9 million, expected to fund operations into the second half of 2027. The company presented new data on its ctLNP and iqDNA platforms.
- Presented data at ASGCT on cell-targeted lipid nanoparticle (ctLNP) platform.
- Disclosed new information about iqDNA platform and RES at ASGCT.
- Cash, cash equivalents, and marketable securities were $233.9 million as of March 31, 2024.
- Company believes cash will fund operations into 2H 2027.
Headline financials
Revenue & EPS history
Generation Bio · Revenue · Quarterly
$4.06M
Revenue by segment
Generation Bio · $2.15M total across 1 segment · Q3 2023
- Collaboration revenue$2.15M—100.0%
Forward guidance
The company continues to believe that its cash, cash equivalents, and marketable securities will fund its operating plan into the second half of 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2024
+3.8%
Avg return
Earnings day
+5.9%
Avg return
5 days after
+8.6%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+61.7%
Q2 2025
Best reaction
-19.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -3.3% | +11.0% | +2.7% | |
| Q2 2025 | +61.7% | +62.0% | +46.9% | |
| Q1 2025 | +4.5% | +0.4% | +4.0% | |
| Q4 2024 | -3.7% | -14.3% | -9.5% | |
| Q3 2024 | +8.7% | -0.5% | -40.8% | |
| Q2 2024 | -2.0% | -3.7% | -10.2% | |
| Q1 2024 | +18.4% | +16.4% | +1.9% | |
| Q4 2023 | +3.1% | +11.5% | +39.4% | |
| Q3 2023 | -1.7% | +7.7% | +46.2% | |
| Q2 2023 | -5.3% | -7.0% | +6.8% | |
| Q1 2023 | -5.0% | -2.7% | +0.4% | |
| Q4 2022 | -8.4% | -10.0% | +15.5% | |
| Q3 2022 | +12.2% | — | — | |
| Q2 2022 | +7.7% | — | — | |
| Q1 2022 | -19.7% | — | — | |
| Q4 2021 | +21.1% | — | — | |
| Q3 2021 | -1.5% | — | — | |
| Q2 2021 | -6.2% | — | — | |
| Q1 2021 | +0.3% | — | — | |
| Q4 2020 | -0.9% | — | — | |
| Q3 2020 | +8.5% | — | — | |
| Q4 2019 | -0.5% | — | — | |
| Q2 2020 | -0.5% | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro